Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
General physical health deterioration08.01.03.0180.003817%Not Available
Blood phosphorus decreased13.11.01.015--Not Available
Anal haemorrhage24.07.02.029; 07.12.03.0040.000336%
Left ventricular dysfunction02.04.02.0110.000392%
Tumour haemorrhage24.07.01.028; 16.32.03.0080.000616%
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000168%Not Available
Ventricular hypokinesia02.04.02.0130.000280%Not Available
Metastatic renal cell carcinoma16.08.02.003; 20.01.04.0050.001567%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000951%
Deep vein thrombosis24.01.02.003--Not Available
Plantar erythema23.03.06.012--Not Available
Madarosis23.02.02.004; 06.06.04.0100.000246%Not Available
Malignant neoplasm progression16.16.01.0050.023180%Not Available
Enterocutaneous fistula23.07.04.017; 07.11.05.0050.000168%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000280%Not Available
Conjunctival hyperaemia06.04.01.0040.000112%Not Available
Metastases to peritoneum16.22.02.008; 07.21.03.0030.000336%Not Available
Ear discomfort04.03.01.0050.000381%Not Available
Eye oedema06.08.03.013--Not Available
Lymphatic disorder01.09.01.003--Not Available
Diastolic dysfunction02.04.02.0220.000112%Not Available
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.0040.000548%Not Available
Musculoskeletal discomfort15.03.04.0010.000571%Not Available
Tumour necrosis24.04.02.013; 16.32.03.0090.000224%Not Available
Nodule08.03.05.0020.000224%Not Available
Haemorrhoidal haemorrhage24.10.02.001; 07.15.03.0020.000224%
Cerebral disorder17.02.10.0170.000302%Not Available
Brain cancer metastatic17.20.04.001; 16.30.04.0010.000168%Not Available
Haemorrhage24.07.01.002--Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 21 Pages